Company Description
- Spanish in-vitro diagnostics company focused on early detection of cancer, using a cutting-edge liquid biopsy technology
- First product is a minimally invasive, accurate and affordable blood-based CRC screening test to detect colorectal cancer and adenoma, allowing early detection and cancer prevention
- Development of a multi-cancer platform to provide further tests asadditional growth opportunities, e.g. for liver and pancreatic cancer
Scope of the Project
- The Company engaged BSV and FCF to support in the valuation of its assets, including the preparation of a detailed sales model reflecting the potential of its diagnostic tests
- The material will serve to validate the products’ market potential in the current CMS reimbursement process
- The comprehensive sales forecast and integrated financial model will support discussions with potential investors
BioScience Valuation’s Role
- Professional preparation of an asset valuation report, including
- Identification of a reasonable target population
- Market size estimations using a top down approach and determination of the sales potential
- Elaboration on reasonable pricing assumptions in different target countries
- Assessment of the development plan and associated risks
- Detailed benchmark analysis
- Risk-adjusted NPV asset valuation
- Sensitivity analyses
- Development of a detailed sales model reflecting the assumptions and results from the asset valuation report
FCF’s Role
- Preparation of all relevant material for the financing process, including an investment teaser and an integrated financial model
- Based on the sales model provided by BSV and a detailed budget provided by the Company, FCF prepared the integrated financial model that projects the financial development of the company over the next years
- The model also includes a sensitivity analysis where specific parameter like revenues or working capital can be adapted to visualize different future scenarios
